Phenol
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Using the evidence pack for Phenol (DB03255). Note: TxGNN’s rank-1 prediction (“acrodermatitis chronica atrophicans”, score 99.95%) has zero supporting evidence and is explicitly flagged in the pack itself as a high-score/no-evidence artefact — as are ranks 2, 3, 4, 6, 7 and 8 (several are drug-name false-positives, e.g. dry eye trials actually testing hydroxychloroquine, AL-38583, omega-3, not phenol). The only candidate with any real evidentiary basis is rank 5, acne keloidalis (L3). I have built this report around that candidate rather than the top TxGNN score, and flagged the other seven as unsupported below — reporting the raw top-ranked prediction as “the” prediction would be misleading for a clinical audience.
Phenol: From Topical Antiseptic/Chemical Peel Agent to Acne Keloidalis
One-Sentence Summary
Phenol has no UK marketing authorisation and no formally recorded original indication; it is historically used as a topical antiseptic and keratolytic (chemical peel) agent. Of eight indications proposed by the TxGNN model, only one — Acne Keloidalis (keloidal folliculitis) — is supported by any actual evidence, with 4 supporting publications (no dedicated clinical trials) and an inferred mechanistic rationale from established chemical-peel dermatology literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on file (0 UK marketing authorisations); historically used as a topical antiseptic/keratolytic (chemical peel) agent |
| Predicted New Indication | Acne Keloidalis (keloidal folliculitis) |
| TxGNN Prediction Score | 99.94% (rank 1,029 of full model output) |
| Evidence Level | L3 (observational/case-series evidence only) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Phenol (flagged as a Blocking/High-severity data gap — see Conclusion). Based on known dermatological use, phenol is a classical deep chemical peeling and keratolytic agent, causing controlled superficial chemical destruction of the epidermis followed by re-epithelialisation. Modified low-toxicity phenol peel formulations have documented use for facial wrinkles, acne scarring and related hyperkeratotic/scar lesions in the dermatology literature (PMID 17204096).
Acne keloidalis (keloidal folliculitis) is a chronic scarring follicular disorder producing hyperkeratotic, keloid-like papules and nodules — mechanistically, the epidermal-remodelling action of chemical peeling is a plausible (if indirect) extension of phenol’s known dermatological use. However, this link is inferred from general chemical-peel literature rather than from any study specifically designed to test phenol in acne keloidalis, so it remains a research hypothesis rather than an established indication.
The remaining seven TxGNN-predicted indications for this drug (acrodermatitis chronica atrophicans, childhood connective-tissue-disease-associated interstitial lung disease, neonatal dermatomyositis, amyopathic dermatomyositis, familial hydroa vacciniforme, severe non-proliferative diabetic retinopathy, and dry eye syndrome) have no credible supporting evidence — either no trials/literature at all, or trials/literature that on inspection test entirely different drugs (hydroxychloroquine, AL-38583, omega-3 fatty acids, berberine, aspirin, antimuscarinics). These are treated as TxGNN false positives and are not carried forward.
Clinical Trial Evidence
Currently no related clinical trials registered for phenol in acne keloidalis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 17204096 | 2007 | Cohort/Case series | The Journal of Dermatology | Modified phenol peel (Exoderm) improved facial wrinkles, acne scars and related skin lesions in Asian patients with reduced side-effect profile |
| 16164153 | 2005 | Review | Cutis | Reviews acne treatment in ethnic skin, including keloid scarring risk and peeling-based approaches |
| 866280 | 1977 | Review | Postgraduate Medicine | Discusses keloidal folliculitis and related dermatoses more common in black patients |
| 4278481 | 1974 | Case report | Fortschritte der Medizin | Historical case report on scalp disease treatment (Crino-Kaban); limited direct relevance |
UK Market Information
Phenol currently has no UK marketing authorisation on file (0 licenses; market status: Not marketed). No product-level dosage form or approved-indication data is available for this substance in the evidence pack.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: TFDA/UK label warnings and contraindications data are currently unavailable for this substance (data gap, Blocking severity) — this must be resolved before any safety assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: No UK marketing authorisation exists for phenol, mechanism-of-action data is unavailable, and the only indication with any supporting evidence (acne keloidalis) rests on inferred mechanistic reasoning from general chemical-peel literature rather than a dedicated trial. The other seven TxGNN-predicted indications for this drug lack credible evidence entirely.
To proceed, the following is needed:
- Resolve the Blocking data gap on TFDA/SmPC warnings and contraindications (required before any S1 safety review)
- Obtain formal mechanism-of-action documentation from DrugBank or equivalent source
- A dedicated preclinical or clinical study testing phenol (not a substitute agent) specifically in acne keloidalis/keloidal folliculitis
- Re-screen the remaining seven predicted indications once genuine phenol-specific evidence (if any) becomes available; current signals for those are considered TxGNN artefacts
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.